KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) Equity Average (2016 - 2026)

Bio-Rad Laboratories has reported Equity Average over the past 17 years, most recently at $7.2 billion for Q1 2026.

  • Quarterly Equity Average rose 7.97% to $7.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.2 billion through Mar 2026, up 7.97% year-over-year, with the annual reading at $7.0 billion for FY2025, 8.41% down from the prior year.
  • Equity Average was $7.2 billion for Q1 2026 at Bio-Rad Laboratories, up from $7.1 billion in the prior quarter.
  • Over five years, Equity Average peaked at $11.9 billion in Q1 2022 and troughed at $6.6 billion in Q1 2025.
  • The 5-year median for Equity Average is $8.4 billion (2023), against an average of $8.3 billion.
  • The largest YoY upside for Equity Average was 16.54% in 2022 against a maximum downside of 37.65% in 2022.
  • A 5-year view of Equity Average shows it stood at $9.0 billion in 2022, then fell by 5.17% to $8.6 billion in 2023, then dropped by 18.07% to $7.0 billion in 2024, then increased by 0.95% to $7.1 billion in 2025, then increased by 0.81% to $7.2 billion in 2026.
  • Per Business Quant, the three most recent readings for BIO's Equity Average are $7.2 billion (Q1 2026), $7.1 billion (Q4 2025), and $6.9 billion (Q3 2025).